

## References

I-186

1. Hayes Inc. Prognosis Overview. Trogarzo (Ibalizumab-uiyk) for Multidrug Resistant HIV-1. March 2018. Accessed April 25, 2018.
2. The American Journal of Health-System Pharmacy. FDA approves novel biologic for resistant HIV infection. *Am J Health-System Pharm.* 2018;75(8):505-506.
3. Trogarzo™ (Ibalizumab-uiyk) for injection [package insert]. Irvine, California, TaiMed Biologics USA Corp. Issued 03/2018.
4. Micromedex®Solutions Compendia. 2018. Ibalizumab.
5. Ibalizumab. Clinical Pharmacology Compendia. Tampa FL: Gold Standard, Inc. 2018.
6. National Institute of Health (NIH). Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV: management of the treatment-experienced patient. *AIDSinfo.* October 17, 2017. Accessed April 26, 2018.